Gunderson Dettmer represented client ImmuneID, a precision immunology company, in its $50 million Series A financing led by Alta Partners and included new investors Alexandria Venture Investments, Redwood Capital Investments, Section 32 and Tekla Capital Management, and existing investors including Arch Venture Partners, Longwood Fund, Pitango HealthTech, In-Q-Tel, Xfund and others.

In the announcement of the transaction, CEO of ImmuneID David Donabedian, Ph.D. said, “This financing from an exceptional group of investors positions us to execute on our ambitious plans to develop a new generation of precision immunology therapeutics.”

The Gunderson deal team was led by Tim Ehrlich and included Georgios Pothoulakis and Jenna Mason.

Companies:
ImmuneID